New drug aims to ease menstrual cramps in phase 3 trial

NCT ID NCT05640232

Recruiting now Symptom relief Sponsor: EMS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial is testing a new drug called CDE100 to see if it relieves menstrual cramp pain better than a current treatment (Buscopan Composto). About 238 women aged 16-35 with moderate to severe cramps will take part. The study is double-blind, meaning neither participants nor doctors know who gets which treatment, and it uses a crossover design so each person tries both drugs at different times.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CDE100 (a combination drug for menstrual cramp pain)
What this could lead to: If successful, this could provide a new, effective option for relieving menstrual cramp pain in women with primary dysmenorrhea.
What could go wrong: This is a Phase 3 trial, but results may not show a significant advantage over existing treatments. Individual responses to pain relief vary, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY DYSMENORRHEA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary dysmenorrhea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY DYSMENORRHEA

Contacts and locations

Locations

EMS
RECRUITING

Hortolândia, São Paulo, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.